Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Recently, Eli Lilly (LLY) revealed that they saw some concerning indicators for their GLP-1 drug in December, which might have been the culprit behind them missing their Q4 revenue guidance by $400M.

Earnings Report 5.786 USD Q2 2025 Earnings Release 08/07/2025 Earnings Report 6.286 USD Q3 2025 Earnings Release 10/30/2025 Earnings Report 7.208 USD Q4 2025 Earnings Release 02/11/2026 Earnings ...

On Jan. 14, Eli Lilly released its guidance for the fourth ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...